The effect of certolizumab drug concentration and anti-drug antibodies on TNF neutralisation

Lea C. Berkhout, Erik H. Vogelzang, Margreet M. Hart, Floris C. Loeff, Lisanne Dijk, Ninotska I.L. Derksen, Roeland Wieringa, W. Astrid van Leeuwen, Charlotte L.M. Krieckaert, Annick de Vries, Michael T. Nurmohamed, Gerrit J. Wolbink, Theo Rispens

Research output: Contribution to journalArticleAcademicpeer-review

17 Citations (Scopus)


OBJECTIVES: Tumour necrosis factor (TNF) inhibitors like certolizumab, elicit an immunogenic response leading to the formation of anti-drug antibodies (ADAs). We sought to mechanistically investigate the relationship between certolizumab concentrations, ADAs, and the effective TNF neutralising capacity in sera of rheumatoid arthritis (RA) patients. TNF neutralising capacity of certolizumab was compared to the neutralising capacity of adalimumab. METHODS: Serum samples were collected from 40 consecutive certolizumab-treated RA patients at baseline and 4, 16, 28 and 52 weeks after treatment initiation [Dutch Trial Register NTR (Nederlands Trial Register) Trial NL2824 no. 2965]. Certolizumab concentration and ADA titre were measured with a certolizumab bridging enzyme-linked immunosorbent assay (ELISA) and a drug-tolerant radioimmunoassay (RIA), respectively. TNF neutralisation by certolizumab and adalimumab, in presence or absence of ADAs, was analysed with the TNF-sensitive WEHI bioassay. RESULTS: Despite a high incidence of ADAs during one year of follow-up (65%; 26/40 patients), certolizumab levels of >10 μg/ml were measured in most patients. The capacity for TNF neutralisation highly correlated with certolizumab serum concentration, whereas no association with ADAs was observed. Similar results were obtained for adalimumab. The relative in vitro neutralising potency was higher for certolizumab compared to adalimumab. CONCLUSIONS: Anti-certolizumab antibodies were detected in a large proportion of patients, but in most cases where ADAs were detected, certolizumab was also present in high concentrations, directly correlating with in vitro neutralising capacity. These results indicate that measurement of certolizumab drug levels, rather than ADAs, have direct clinical significance.

Original languageEnglish
Pages (from-to)306-313
Number of pages8
JournalClinical and experimental rheumatology
Issue number2
Early online date30 Aug 2019
Publication statusPublished - 1 Mar 2020

Cite this